Back to Freepaper Session
Platelet rich growth factors (PRGF) treatment of corneal and ocular surface diseases
Session Title: Cornea
Session Date/Time: Sunday 16/02/2014 | 08:30-11:00
Paper Time: 10:15
Venue: Linhart Hall (Level -2)
First Author: : KalliopiDiamantopoulou GREECE
Co Author(s): : Elisabeth Patsoura Bettina Neureither Ioanna Metaxaki Spyros Georgaras
A pilot study to evaluate the effectiveness of platelet (PRGF) factors in corneal and ocular surface disorders refractory to other conventional treatment.
Οphthalmos Research and Therapeutic Institute
Case series of 32 studies with surface corneal disease, including dry eye disease, toxic keratopathy (glaucoma drug related), recurrent corneal erosions, neurotrophic keratitis and bullous keratopathy were treated with plasma rich growth factors for a period of 6 weeks. The patients were followed up every week for a month and then monthly for 6 months. The patients continued their previous medication during PRGF treatment.
Subjective improvement was mentioned by all patients. Beneficial effect seems to be maintained in all eyes at the end of the three months period. Epitheliopathy improved in all cases. Corneal erosions healed within 2 weeks. No adverse effect was noted following cessation of therapy. We had to restart treatment in 4 eyes within two months.
Platelet rich growth factors appear to be a promising evolving field in the treatment of specific ocular diseases FINANCIAL INTEREST: NONE